TABLE 2-4 Biotechnology Medicines or Vaccines Approved by the Food and Drug Administration, 1993

Product

Indications

Company

Year Approved

Beta interferon

Multiple sclerosis

Chiron

1993

DNAse

Cystic fibrosis

Genentech

1993

Factor VIII

Hemophilia

Genentech, Genetics Institute

1993

IL-2

Renal cell cancer

Chiron

1992

Indium-111-labeled antibody

Cancer imaging

Cytogen

1992

Aglucerase

Gaucher's disease

Genzyme

1991

G-CSF

Adjunct to chemotherapy

Amgen

1991

GM-CSF

Bone marrow transplant

Immunex

1991

Hyaluronic acid

Ophthalmic surgery

Genzyme

1991

CMV immune globulin

Prevention of rejection in organ transplants

MedImmune

1990

Gamma interferon

Chronic granulomatous disease

Genentech

1990

PEG-adenosine deaminase

Immune deficiency

Enzon

1990

t-PA

Myocardial infarction, pulmonary embolism

Genentech

1990

Erythropoietin

Anemia associated with renal failure, AIDS, cancer

Amgen

1989

Hepatitis B antigens

Diagnosis

Biogen

1987

Alpha interferon

Cancer, genital warts, hepatitis

Biogen, Genentech

1986

Hepatitis B vaccine

Prevention

Biogen, Chiron

1986

Human growth hormone

Deficiency

Genentech

1985

Human insulin

Type I diabetes

Genentech

1982

 

SOURCE: "Datawatch: Biotechnology and Innovation Progress Reports," in Health Affairs, Summer, 1994.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement